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GpDpLQ1237—A type II Collagen 
Neo-epitope Biomarker of 
Osteoclast- and Inflammation-
Derived Cartilage Degradation  
in vitro
Henrik Löfvall1,2, Anna Katri1,3, Aneta Dąbrowska1, Morten A. Karsdal1, Yunyun Luo1, Yi He1, 
tina Manon-Jensen1, Morten H. Dziegiel4, Anne-Christine Bay-Jensen1, Christian S. Thudium1 
& Kim Henriksen1
C-telopeptide of type II collagen (CTX-II) has been shown to be a highly relevant biomarker of cartilage 
degradation in human rheumatic diseases, if measured in synovial fluid or urine. However, serum or 
plasma CTX-II have not been demonstrated to have any clinical utility to date. Here, we describe the 
GpDpLQ1237 ELISA which targets the EKGPDPLQ↓ neo-epitope, an elongated version of the CTX-II neo-
epitope (eKGpDp↓), speculated to be a blood-precursor of CTX-II generated by the cysteine protease 
cathepsin K. Human osteoclast cartilage resorption cultures as well as oncostatin M and tumour necrosis 
factor α-stimulated bovine cartilage explant cultures were used to validate GPDPLQ1237 biologically 
by treating the cultures with the cysteine protease inhibitor E-64 and/or the matrix metalloproteinase 
(MMP) inhibitor GM6001 to assess the potential contributions of these two protease classes to 
GpDpLQ1237 release. Cartilage resorption-derived GPDPLQ1237 release was inhibited by E-64 (72.1% 
inhibition), GM6001 (75.5%), and E-64/GM6001 (91.5%), whereas CTX-II release was inhibited by GM6001 
(87.0%) but not by E-64 (5.5%). Cartilage explant GPDPLQ1237 and CTX-II release were both fully inhibited 
by GM6001 but were not inhibited by E-64. No clinically relevant GPDPLQ1237 reactivity was identified in 
human serum, plasma, or urine from healthy donors or arthritis patients. In conclusion, the GPDPLQ1237 
biomarker is released during osteoclast-derived cysteine protease- and MMP-mediated cartilage 
degradation in vitro, whereas CTX-II release is mediated by MMPs and not by cysteine proteases, as 
well as from MMP-mediated cartilage degradation under a pro-inflammatory stimulus. These findings 
suggest that GPDPLQ1237 may be relevant in diseases with pathological osteoclast activity and cartilage 
degradation. Further studies are required to validate the neo-epitope in human samples.
C-telopeptide of type II collagen (CTX-II) is a biomarker of type II collagen degradation, indicative of cartilage 
degradation. Degradation of joint extracellular matrices (ECMs), including cartilage, is a key feature of multi-
ple types of arthritis, including osteoarthritis (OA) and rheumatoid arthritis (RA). Urinary and synovial fluid 
(SF) CTX-II, unlike serum CTX-II, is a highly relevant biomarker for OA1–3 with some relevance for RA4. OA 
incidence and progression5,6, severity6,7–8, bone marrow lesions9, osteophytes10 and pain11 have been associated 
with CTX-II, although pain associations have varied11. In RA, CTX-II has been shown to predict disease pro-
gression12–15, treatment efficacy13, bone mineral density (BMD) reduction16 and synovitis16. However, no studies 
have been published to date that demonstrate any clinical utility of serum or plasma CTX-II, although it has been 
demonstrated to be very useful in animal models with experimentally induced joint destruction17–21. Additionally, 
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SF and urine sampling have their own drawbacks, particularly in terms of practicality. SF collection is more com-
plicated and inconvenient than collecting either serum, plasma, or urine and is also a more complex biological 
matrix to work with. Furthermore, both urine and SF analyte concentrations require volume adjustment due to 
e.g. fluid intake, arthroscopic lavage or joint effusion3,22. Urine CTX-II is also known to have diurnal variation23, 
which necessitates a strict urine sampling procedure. As blood is more frequently sampled than urine and SF, a 
blood-based CTX-II-like biomarker would be more accessible, practical, and reliable for assessing cartilage deg-
radation, if clinical utility could be demonstrated.
CTX-II assays detect C-telopeptide fragments of type II collagen, the major ECM component of articular 
cartilage, with a neo-epitope24 formed by proteolytic cleavage (EKGPDP↓)25 during degradation of cartilage by 
MMPs26–28. The neo-epitope has been immunolocalised to areas of cartilage damage, around chondrocytes, areas 
of vascularization close to the subchondral bone, and the bone–cartilage interface29—suggesting possible contri-
bution of osteoclasts to CTX-II. Osteoclasts play important roles in diseases with progressive joint destruction, 
particularly for bone erosion in diarthrodial joints in RA30–34. However, their role in cartilage alterations—such 
as those seen in OA—is poorly understood, albeit strongly implicated35. An elongated CTX-II neo-epitope 
(EKGPDPLQ↓) has been previously described in patent literature26–28, where it has been suggested to be gener-
ated by cathepsin K-mediated cleavage of calcified cartilage, to be osteoclast-specific, and to be present in blood 
while being absent or only present in trace amounts in urine and SF. In the patents, proteases in the kidneys and/
or liver were described to potentially remove the C-terminal -LQ of the EKGPDPLQ neo-epitope to generate the 
urinary forms of the C-telopeptide—EKGPDP or smaller26–28. Due to potential differences in generation and/
or processing from the EKGPDP neo-epitope, the EKGPDPLQ neo-epitope may be an interesting blood-based 
biomarker for studies of degenerative joint diseases.
To date no peer-reviewed clinical, in vivo, or in vitro studies using assays detecting the EKGPDPLQ 
neo-epitope have been published. In this study we investigated the release of this neo-epitope from non-calcified 
articular cartilage, in in vitro models of cartilage degradation derived from osteoclasts36 or inflammation24, using 
the novel competitive GPDPLQ1237 enzyme-linked immunosorbent assay (ELISA). The validated assay was then 
used to test for GPDPLQ1237 reactivity in human serum, plasma, and urine.
Results
Specificity of the GPDPLQ1237 ELISA. The target sequence of the GPDPLQ1237 ELISA, 1230EKGPDPLQ1237, 
was analysed for homology to other human and animal proteins using the NPS@: Network Protein Sequence 
Analysis PattInProt search against the UniProtKB/Swiss-prot database. The target sequence was found to be 
unique to the type II collagen alpha 1 chain, and was fully conserved in human, cow, and rat. When allowing for 
one mismatch in the sequence, it was also conserved in mouse but not in any other animal proteins.
The specificity of the competitive GPDPLQ1237 ELISA was evaluated by analysing the reactivity towards the 
standard peptide as well as two elongated and two truncated standard peptides, peptide sequences are described 
in Table 1. The antibody only reacted with the standard peptide and produced a dose-dependent response 
(Fig. 1a), increased elongated and truncated peptide concentrations only resulted in minor optical density (OD) 
displacements (Fig. 1b). These data suggest that GPDPLQ1237 is highly specific for the neo-epitope and does not 
cross-react with the CTX-II neo-epitope, i.e. the Truncated −2 peptide.
Technical validation of the GPDPLQ1237 ELISA. Technical validation tests were performed to evaluate 
the performance of the GPDPLQ1237 ELISA. The validation steps and the performance are shown in Table 2. 
Samples measured linearly in the range 0.8–8.0 ng/ml in dilution recovery tests, samples above 7–8 ng/ml dis-
played reduced linearity. Samples above 8 ng/ml should be diluted further in assay buffer and measured again. 
Furthermore, despite obtaining highly reproducible signals in pig, horse, sheep and donkey sera, these signals 
could not be technically validated by dilution recovery. Hence, sera from these species were only used for deter-
mining inter- and intra-assay variation. GPDPLQ1237 was, however, abundant in foetal bovine serum (FBS), where 
it diluted linearly. Human sera, plasma, and urine from healthy donors or RA and OA patients, as well as rat 
plasma, did not produce sufficient signals for technical validation.
GpDpLQ1237 release from bovine articular cartilage explants. The generation of the GPDPLQ1237 
neo-epitope from articular cartilage biopsies undergoing inflammatory degradation was tested in samples 
derived from bovine cartilage explant (BEX) cultures stimulated with oncostatin M (OSM) and tumour necro-
sis factor α (TNFα, OT). Although there was substantial variation in GPDPLQ1237 induction by OT in terms 
Peptide identifier Amino acid sequence
Biotinylated peptide biotin-EKGPDPLQ
Standard peptide EKGPDPLQ
Elongated +1 peptide EKGPDPLQY
Elongated +2 peptide EKGPDPLQYM
Truncated −1 peptide EKGPDPL
Truncated −2 peptide EKGPDP
Immunogenic peptide KLH-CEKGPDPLQ
Table 1. Synthetic peptides used for development and validation of the GPDPLQ1237 competitive ELISA. 
Abbreviations: KLH, keyhole limpet haemocyanin.
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of magnitude and kinetics between the three performed experiments, the overall inhibition patterns were the 
same as in the following representative experiment (Fig. 2). GPDPLQ1237 data from an additional experiment 
is shown in Supplementary Fig. S1. The GPDPLQ1237 neo-epitope was detected in the OT culture supernatants 
after approximately 10 days of culture (Fig. 2a), but GPDPLQ1237 levels remained at baseline levels when adding 
the broad-spectrum MMP inhibitor GM6001 to the culture. The OT response was not inhibited by the cysteine 
protease inhibitor E-64, albeit with considerable variation between explants, but there was a delay in GPDPLQ1237 
release in the E-64 condition relative to the OT condition and the E-64 condition had higher GPDPLQ1237 lev-
els than the OT condition at the final time points, findings that were also present in additional experiments 
(Supplementary Fig. S1). The apparent decrease in GPDPLQ1237 levels in the OT condition at the final time 
points compared to earlier time points (Fig. 2a) was, however, not a consistent finding (Supplementary Fig. S1). 
The GPDPLQ1237 area under the curve (AUC) analysis (Fig. 2c) demonstrates that OT induced a statistically 
significant increase in GPDPLQ1237 levels (129.9 ± 58.6 ng/ml, P = 0.034) that was fully inhibited by GM6001 
(10.6 ± 1.6 ng/ml, P = 0.015), but not by E-64 (367.2 ± 212.2 ng/ml, P > 0.999). Similar results were also found 
in additional experiments (Supplementary Fig. S1). CTX-II release, measured at a selection of relevant time 
points, followed a very similar pattern to that of GPDPLQ1237 release (Fig. 2b); OT induced CTX-II release while 
GM6001, but not E-64, inhibited the CTX-II induction to baseline levels. Unlike GPDPLQ1237 release, CTX-II 
release in the E-64 condition did not appear to have a delayed onset relative to the OT condition. Increased 
CTX-II levels were observed in the E-64 condition at late time points, similarly to the GPDPLQ1237 data. The 
CTX-II AUC analysis (Fig. 2d) reveals that OT induced a marked increase in CTX-II levels, albeit not statistically 
significant (5695.0 ± 1608.0 pg/ml, P = 0.345), that was fully inhibited by GM6001 (283.2 ± 0.0 pg/ml, P = 0.010), 
but not by E-64 (23309.0 ± 14381.0 pg/ml, P > 0.999).
GpDpLQ1237 release from articular cartilage resorption. The release of GPDPLQ1237 from human 
osteoclasts cultured on bovine non-calcified articular cartilage was measured in three individual resorption 
assays. As demonstrated in a representative experiment, the absolute GPDPLQ1237 levels (Fig. 3a) markedly 
increased in the supernatants of cultures with osteoclasts compared to background levels in cultures without 
osteoclasts, as did CTX-II levels (Fig. 3b). The background measurements were subtracted from the osteoclast 
measurements from each assay, and the background-subtracted data were subsequently normalised to the vehicle 
condition mean. The normalised data from each condition were averaged and pooled with the data from the 
other resorption assays to generate the final data set, where n corresponds to the number of resorption assays per 
condition. The background-subtracted GPDPLQ1237 release (Fig. 3c) was inhibited by both E-64 (72.1 ± 14.0% 
inhibition, P = 0.007) and GM6001 (75.5 ± 13.7% inhibition, P = 0.006) compared to the vehicle condition. 
The GPDPLQ1237 levels were reduced further by E-64/GM6001 combined (91.5 ± 0.7% inhibition, P = 0.004), 
although this was not statistically significant compared to E-64 or GM6001 alone (P = 0.659 and P = 0.769). 
Figure 1. Specificity of the GPDPLQ1237 monoclonal antibody. Monoclonal antibody reactivity towards 
the standard peptide as well as elongated and truncated standard peptides was tested in the competitive 
GPDPLQ1237 ELISA. The OD displacement is shown in the peptide concentration range of the standard curve 
(a) as well as at increased peptide concentrations (b). Results are shown as OD450-650 nm as a function of peptide 
concentration.
Technical validation procedure GPDPLQ1237 performance
Detection range (LLOD–ULOD) 0.7–19.4 ng/ml
Estimated linear range 0.8–8.0 ng/ml
Dilution recovery in linear range† 106% (99–119%)
Inter-assay variation† 6% (5–8%)
Intra-assay variation† 2% (0–2%)
Freeze/thaw recovery (4 cycles)† 100% (99–102%)
Table 2. Technical validation of the GPDPLQ1237 competitive ELISA. †Percentages are reported as means with 
ranges shown in brackets. Abbreviations: LLOD, lower limit of detection; ULOD, upper limit of detection.
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As expected, GPDPLQ1237 was not detectable above background levels in supernatants from resorbed cortical 
bone (data not shown). CTX-II release (Fig. 3d) in the cartilage resorption cultures was inhibited by GM6001 
(87.0 ± 6.9% inhibition, P = 0.019) but not by E-64. E-64/GM6001 combined did not result in further inhibition 
of CTX-II release (61.1 ± 11.6% inhibition, P = 0.246). These findings indicate that the release of GPDPLQ1237 
and CTX-II neo-epitopes from articular cartilage undergoing osteoclast-mediated degradation are not mediated 
by the same proteases; while we demonstrated that both MMPs and cysteine proteases contribute to GPDPLQ1237 
release during osteoclastic cartilage resorption, only MMPs contributed to CTX-II release.
Immunolocalization of the GPDPLQ1237 neo-epitope. Tibia obtained from young healthy Lewis rats 
were used to immunolocalise the GPDPLQ1237 neo-epitope. GPDPLQ1237 staining was observed at the articular 
cartilage and the growth plate, while no staining was observed when using a negative control antibody (Fig. 4). 
The articular cartilage stained for GPDPLQ1237 in the ECM and in pericellular spaces throughout all cartilage 
layers, albeit at varying intensity, while the growth plates stained mainly between the columns of proliferating 
cells—not in the immediate pericellular ECM—and at the proximal bone–cartilage interface. Intermittent growth 
plate staining was also observed in the ossification zone.
Discussion
There is an unmet need for novel biomarkers of cartilage degradation for rheumatic diseases, and for blood-based 
biomarkers in particular. The EKGPDPLQ neo-epitope has been previously described in patent literature26–28, 
but to our knowledge no peer-reviewed articles measuring EKGPDPLQ release from cartilage, calcified or 
non-calcified, have been published. In patent literature, the EKGPDPLQ neo-epitope has been described to repre-
sent the degradation of calcified cartilage by cathepsin K26–28, if analysed in blood. However, using the competitive 
GPDPLQ1237 ELISA we could quantify both cysteine protease- and MMP-mediated release of the EKGPDPLQ 
neo-epitope from different models of non-calcified cartilage degradation in vitro.
In our study, we detected MMP-derived GPDPLQ1237 release from non-calcified cartilage in a model of 
inflammatory cartilage degradation. In the BEX OT model, the GPDPLQ1237 protease profile—with inhibition 
by GM6001 and no inhibition by E-64—and kinetics were similar to those of CTX-II. These CTX-II results also 
closely resembled previously reported CTX-II37,38 and C2M39 data in the BEX OT model. The C2M neo-epitope, 
like CTX-II, is generated from type II collagen degradation predominantly by MMPs39. C2M has previously 
been shown to be able to distinguish between healthy subjects and patients or between subsets of patients with 
Figure 2. GPDPLQ1237 and CTX-II release into BEX supernatants upon stimulation and inhibition of MMP 
activity. The BEX cultures were untreated (w/o), treated with OSM and TNFα (OT) without protease inhibitors, 
or OT with the protease inhibitors GM6001 (OT + GM6001) or E-64 (OT + E-64). GPDPLQ1237 (a,c) and 
CTX-II (b,d) data from one representative experiment are presented as the mean biomarker levels per group 
at different time points throughout the experiment (a,b) and as the AUCs of each individual explant and their 
means (c,d). Error bars represent the SEMs. Statistical significance relative to the OT condition in the AUC data 
is indicated by *P < 0.05.
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arthritic diseases, such as OA39,40, RA41–43 and ankylosing spondylitis44,45, and is therefore a relevant biomarker 
for assessing type II collagen resorption in in vitro models. Interestingly, CTX-II release is typically increased 
by E-64 treatment in the BEX OT model37,38, whereas C2M release is not increased to a statistically significant 
degree39, but we did not detect any significant differences in GPDPLQ1237 or CTX-II release between the OT and 
the OT+ E-64 conditions. The overall effect of E-64 on both GPDPLQ1237 and CTX-II AUC release was highly 
variable and not statistically significant, indicating that cysteine proteases did not have a net effect that played any 
major role in release of either biomarker in this model, although it is possible that specific cysteine proteases may 
contribute differently. The lack of overall inhibition of GPDPLQ1237 release by E-64 is likely due to low cysteine 
protease activity in this model, even though cathepsin K induction has previously been demonstrated in the 
BEX OT model by immunohistochemistry37. Similarly to our findings, the cathepsin K-specific type II collagen 
neo-epitope C2K77 has been reported to not be detectable above background levels in OT-stimulated equine 
cartilage explants46, indicating that cathepsin K-mediated type II collagen degradation—and potentially the con-
tribution of other cysteine proteases as well—is low in this model.
The reason for the apparent delayed release of GPDPLQ1237 in the E-64 condition as well as the increased 
GPDPLQ1237 and CTX-II levels at late time points, compared to the OT condition, remains unclear. Parts of these 
effects are likely explained by the large inter-explant variation that is common for this model system, although 
we did observe both the delayed GPDPLQ1237 onset and the elevated biomarker levels at final time points in 
several experiments. The delay in GPDPLQ1237 release did not appear to affect overall biomarker levels over the 
culture period used in this experiment, and the biological relevance of this putative delay is therefore uncertain. 
Interestingly, no corresponding delay was observed in CTX-II release upon E-64 treatment, suggesting that there 
might be a difference between GPDPLQ1237 and CTX-II in the kinetics of biomarker release at intermediate time 
points that may be related to cysteine protease activity. Speculatively, the delay may be a result of E-64 temporarily 
inhibiting early cysteine protease-mediated biomarker release, which is detectable by the GPDPLQ1237 assay but 
Figure 3. Osteoclast-derived GPDPLQ1237 and CTX-II release from bovine articular cartilage. Background 
biomarker levels of GPDPLQ1237 (a) and CTX-II (b) measured in media from cultures with only cartilage 
(Background, n = 2) and cultures with osteoclasts and cartilage (Osteoclasts, n = 6) in one representative 
resorption assay, presented as means with SEMs. Background levels were subtracted from the GPDPLQ1237 
and CTX-II levels in each individual resorption assay followed by normalisation to the vehicle condition. The 
normalised data were averaged followed by pooling of the data, resulting in n = 2 for E-64/GM6001 and n = 3 
for other conditions where n is the number of resorption assays featuring the condition, and the background-
reduced normalised GPDPLQ1237 (c) and CTX-II (d) levels are presented as the means of all resorption assay 
means where error bars represent the SEMs. Statistical significance relative to the vehicle condition in the 
background-reduced data is indicated by *P < 0.05 and **P < 0.01.
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not by the CTX-II assay, but the inhibition ultimately fails and results in rapid onset of cysteine protease-mediated 
cartilage degradation and GPDPLQ1237 release.
The increased GPDPLQ1237 release at late time points in the E-64 condition may potentially be mediated by 
inhibition of cathepsin B. Cathepsin B is a dipeptidyl carboxypeptidase47 that is upregulated in interleukin-1 (IL-
1)48 and TNFα/IL-1β-stimulated49 chondrocytes and may potentially process the EKGPDPLQ neo-epitope into 
the EKGPDP neo-epitope. Although cathepsin B is known to generate CTX-II during in vitro cleavage—while 
cathepsins D, K, L and S do not—and may even be able to degrade CTX-II neo-epitopes to some extent50, it is 
unclear how much cathepsin B actually contributes to CTX-II release in the BEX OT model. As demonstrated in 
Figure 4. Immunolocalization of the GPDPLQ1237 neo-epitope in rat tibia. Representative micrographs of 
rat tibial articular cartilage and growth plate stained with the NB427-5G11-4W3 GPDPLQ1237 (GPDPLQ1237) 
monoclonal antibody (brown) or a negative control antibody, counterstained with Mayer’s haematoxylin 
(purple). Micrographs were obtained using a 10x (first and third row) and a 20x (second and fourth row) 
objective. Scale bars represent 100 µm.
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our study, cysteine protease inhibition with E-64 does not reduce CTX-II release in the BEX OT model but rather 
appears to have no effect or to increase it, as has been previously reported37,38, indicating that the contribution 
of cathepsin B to type II collagen degradation, CTX-II release, GPDPLQ1237 degradation, and/or CTX-II degra-
dation in this model is modest compared to the net neutral or positive effects that cysteine protease inhibition 
appears to have on CTX-II levels at late time points. Furthermore, the overall lack of effect of E-64 in GPDPLQ1237 
and CTX-II AUC data and the increased release of both GPDPLQ1237 and CTX-II at late time points suggest that 
the late increase of GPDPLQ1237 levels is not a result of inhibited conversion of the GPDPLQ1237 epitope into 
CTX-II by cysteine proteases—as E-64 treatment only resulted in delayed GPDPLQ1237 induction while it did 
not increase and decrease overall GPDPLQ1237 and CTX-II release, respectively. While cysteine proteases do not 
appear to have a significant net effect on overall GPDPLQ1237 and CTX-II release, cathepsin B may still convert 
GPDPLQ1237 into CTX-II in this model. If cathepsin B mediates both GPDPLQ1237 and CTX-II degradation at 
similar rates it is possible that neither of these effects would be detectable during cysteine protease inhibition, 
or indeed cathepsin B inhibition. The potential role of cathepsin B in conversion of GPDPLQ1237 into CTX-II is 
interesting and could be investigated further using cathepsin B-specific inhibitors such as CA07451, potentially in 
BEX cultures stimulated with IL-1, but this was considered to be outside the scope of the current study as cysteine 
protease inhibition did not appear to have substantial impact on the overall release of either biomarker in the 
BEX OT model.
As for the observed decline in biomarker release in the OT condition at very late time points, this is similar to 
previously reported results in other type II collagen neo-epitopes at very late time points, both in OT and OT+ 
E-64 conditions38,39, but it was not a consistent finding in our study, underscoring the somewhat variable nature 
of cartilage explant cultures. As it was not consistent and was observed with both GPDPLQ1237 and CTX-II, albeit 
to a lesser extent with CTX-II, the decline is unlikely to be a result of interconversion of the neo-epitopes by 
cathepsin B or to represent important changes to type II collagen degradation over time. The decline may rather 
be related to e.g. destruction of the cartilage or depletion of the ECM, as has been previously described in this 
model37, or the substantial inter-explant variation that is often observed in the BEX OT model.
In our model of osteoclastic cartilage resorption, GPDPLQ1237 release was found to be mediated by both 
cysteine proteases and MMPs. Cathepsin K is the predominant cathepsin in osteoclasts52,53 and it has also been 
demonstrated to be crucial for type I collagen degradation by osteoclasts during normal bone resorption52–56. 
Furthermore, the cathepsin K-specific antiresorptive odanacatib inhibits the majority of CTX-I release (approxi-
mately 80% inhibition) during bone resorption in vitro55,56 with an effect size similar to that of E-6457. Osteoclasts 
are also thought to utilize several other cathepsins and cysteine proteases for bone resorption58,59, but cathepsin K 
is clearly essential for normal resorptive function and type I collagen resorption even though MMPs can compen-
sate to some extent when cathepsin K is inhibited60. Accordingly, it is likely that the cysteine protease-mediated 
GPDPLQ1237 release from cartilage is mediated at least in part by cathepsin K, but the precise cysteine proteases 
underlying GPDPLQ1237 release during cartilage resorption would need to be verified using specific inhibitors, 
like odanacatib, or cathepsin K-deficient osteoclasts. Contrary to GPDPLQ1237 release, CTX-II release from car-
tilage resorption was mediated by MMPs but not by cysteine proteases. This is similar to previous studies of 
CTX-II release from cartilage digested by MMPs or cathepsins D, K, L and S in vitro50,61, although CTX-II has 
been shown to be generated by cathepsin B50. Thus, GPDPLQ1237 appears to be a biomarker that is generated 
through direct osteoclastic cartilage resorption mediated by cysteine proteases—likely in part by cathepsin K—
and MMPs whereas CTX-II release is primarily mediated by MMPs in this model, similarly to previous studies 
of C2M release in this model36.
The potential contribution of MMPs, cysteine proteases and articular cartilage to GPDPLQ1237 neo-epitope 
levels may differ in vivo. GPDPLQ1237 levels in human serum, plasma and urine, obtained from healthy donors, 
OA patients, or RA patients, or rat plasma were too low to perform technical validation of the assay in these 
matrices. Further work would be required to validate the neo-epitope’s relevance in human samples. Although we 
do not know the reason underlying the lack of substantial GPDPLQ1237 signals in serum, plasma, and urine in this 
study, it may be due to insufficient sensitivity of the ELISA or processing of the EKGPDPLQ neo-epitope into the 
EKGPDP neo-epitope26–28, followed by excretion, resulting in low levels or transient presence of the EKGPDPLQ 
neo-epitope in serum and plasma. This would require further testing and validation, potentially on more sensitive 
assay platforms or using a redesigned assay that may allow for improved sensitivity towards the analyte. However, 
preliminary attempts to change the assay buffer or assay design, using e.g. a sandwich ELISA instead of a com-
petitive ELISA, did not improve sensitivity towards the analyte in serum or plasma. Alternatively, GPDPLQ1237 
may be measured in SF which may be a more biologically relevant matrix, although the patents proposed oth-
erwise26–28. SF measurements were outside the scope of the current study as we aimed to develop a blood- or 
urine-based biomarker, due to the limited availability of SF and its invasive sampling method, and GPDPLQ1237 
presence in SF would need to be investigated further. Other elongated or truncated CTX-II neo-epitopes26–28 may 
also be relevant targets in the search for CTX-II-like neo-epitopes in blood.
Despite the lack of GPDPLQ1237 in human and rat body fluids, our immunohistochemical analysis of 
GPDPLQ1237 presence in rat tibia suggests that the neo-epitope can be generated through naturally occurring 
cartilage turnover, at least in the joints of young adult rats. GPDPLQ1237 was observed in the articular cartilage 
ECM in healthy Lewis rats. CTX-II is primarily present in articular cartilage during disease, e.g. collagen-induced 
arthritis, in rats18,62 but it has also been described in some healthy rats62. In our study, GPDPLQ1237 was present 
at various levels in all layers of the articular cartilage ECM in healthy rats, unlike CTX-II which is only present 
in some healthy rats62, which suggests that articular cartilage GPDPLQ1237 may be a feature of physiological car-
tilage turnover in rats, whereas CTX-II is a better indicator of pathology. Additionally, the articular cartilage 
GPDPLQ1237 staining patterns differ from those reported for CTX-II; CTX-II stains the superficial matrix in 
the upper zone as well as around round and flat chondrocytes in the upper and deep zones62, although it is 
unclear which treatments the rats that were used in the reported illustrations were subjected to in this report. 
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Similar CTX-II staining patterns have also been reported in human OA knees29. Interestingly, CTX-II frequently 
stains the bone–cartilage interface in these tissues29, but human growth plate stainings were not available for 
comparison to our GPDPLQ1237 findings. When examining the rat growth plates, we found that GPDPLQ1237 
primarily stained the proximal bone–cartilage interface and the ECM between the columns of proliferating chon-
drocytes, but not the pericellular matrix. We also observed intermittent GPDPLQ1237 staining in the ossification 
zone, where osteoclasts degrade the calcified cartilage during endochondral ossification63. Growth plates in both 
healthy rats and arthritic rats can stain positive for the CTX-II neo-epitope, but they do so in a different pattern 
than GPDPLQ123762. CTX-II staining was reported primarily in the pericellular ECM around the chondrocytes in 
the illustrative growth plate staining62. Although the GPDPLQ1237 and CTX-II staining patterns clearly differ, the 
presence of both GPDPLQ1237 and CTX-II at healthy rat growth plate suggests that they may both be generated as 
part of endochondral ossification during bone growth. This conclusion is further supported by both GPDPLQ1237 
and CTX-II17 being abundant in FBS, as endochondral ossification is an important part of bone development 
during foetal development. Similarly, both CTX-II and C2M are high in serum from one-month-old rats but 
decrease significantly over time as they age64.
Other type II collagen neo-epitope antibodies, such as C2M and C2K77 have also been described to be pres-
ent in OA cartilage. C2M is known to be present in both non-calcified and calcified cartilage beneath cartilage 
surface irregularities, surface erosions, and cartilage lesions39. Similarly, C2K77 staining is increased in equine 
OA cartilage sections with focal cartilage degeneration and partial thickness fissures46, as well as in areas of pro-
teoglycan loss65. C2K77 staining has also been demonstrated in human knee OA cartilage lesions where it mostly 
stained the matrix around chondrocytes in the lesional area of the tissue, whereas little staining was observed in 
non-lesion areas or with a negative control antibody65. These immunohistochemical stainings of the type II col-
lagen neo-epitopes CTX-II, C2M and C2K77 demonstrate how they can be used to further our understanding of 
disease processes in different parts of joints, but descriptions of C2M, C2K77 and CTX-II stainings of healthy car-
tilage are limited. In our study we observed substantial GPDPLQ1237 staining in both cartilage and growth plates 
in healthy rat specimen, which would make it difficult to make any conclusions on GPDPLQ1237 generation in 
diseased specimen. However, our immunohistochemical analysis does demonstrate that GPDPLQ1237 is generated 
biologically and is present in rat tissues, even though we were not able to measure and validate GPDPLQ1237 in 
rat plasma. Immunohistochemical studies using human tissues would be of interest to investigate if GPDPLQ1237 
staining is also a feature of mature human cartilage or if it is specific to diseased human cartilage.
In conclusion, the results of our study indicate that the GPDPLQ1237 neo-epitope—EKGPDPLQ—is a 
non-calcified cartilage degradation biomarker that can be generated during osteoclastic resorption and inflam-
matory degradation by cysteine proteases and/or MMPs in vitro, and during physiological cartilage degradation 
in rats. GPDPLQ1237 is a promising biomarker for studies of cartilage degradation in vitro, but additional work is 
required to validate the relevance of the neo-epitope in vivo.
Methods
Target selection and peptide sequences. The GPDPLQ1237 target sequence, as described in patents26–28, 
is a C-terminal neo-epitope formed by proteolytic cleavage of type II collagen: 1230EKGPDPLQ↓YMR1240. 
A sequence of 8 amino acids adjacent to the cleavage site (1230EKGPDPLQ↓1237) was chosen as the target. The 
sequence was analysed for homology to other human and animal proteins using NPS@: Network Protein 
Sequence Analysis PattInProt search66 with the UniProtKB/Swiss-prot database.
Synthetic peptides (GenScript, Piscataway, NJ) were used for monoclonal antibody production and validation 
of the ELISA. An overview of the peptides used is shown in Table 1. A biotinylated peptide (biotin-EKGPDPLQ) 
was used as a coating peptide for streptavidin-coated microtiter plates. Standard curves were generated using the 
standard peptide (EKGPDPLQ). The specificity of the antibody was tested using two elongated and two truncated 
standard peptides, that have been previously described26–28. An immunogenic peptide was generated by covalent 
cross-linkage of a standard peptide with an added N-terminal cysteine residue to keyhole limpet haemocyanin 
(KLH) carrier protein using succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC, Thermo 
Scientific, Waltham, MA).
Generation of monoclones. Four to six-week-old female Balb/C mice were housed (five mice per cage, 
standard wood chips bedding enriched with huts, nesting material and sticks) at the Nordic Bioscience (Beijing) 
animal facility (21–23 °C, 55–65% relative humidity, 12 hours light/dark cycle) with ad libitum access to food and 
water. The mice were immunised by subcutaneous injection of 200 μl emulsified antigen containing 60 μg immu-
nogenic peptide mixed with Freund’s complete adjuvant (Sigma-Aldrich, St. Louis, MO). Repeated immuniza-
tions with 30 μg immunogenic peptide mixed with Freund’s incomplete adjuvant (Sigma-Aldrich, St. Louis, MO) 
were performed in 2-week intervals until stable serum titres were obtained. The mice with the highest titre and 
highest reactivity towards the target, tested in competitive ELISAs using the biotinylated, standard, elongated and 
truncated peptides, were allowed to recover for four weeks followed by a booster injection of 50 μg immunogenic 
peptide in 100 μl 0.9% NaCl solution, administered intraperitoneally. When serum titres were high and stable, the 
mice were euthanised by concussion followed by cervical dislocation and isolation of their spleens. Hybridoma 
cells were generated through fusion of isolated splenocytes with SP2/0 myeloma cells as previously described67. 
Limited dilution procedures were used to generate monoclonal cultures.
Specificity of monoclonal antibodies. The reactivity of the monoclonal supernatants was evaluated in 
a competitive ELISA by testing for OD displacement using the standard peptide and lack of displacement by 
elongated and truncated standard peptides, using 4 ng/ml biotinylated peptide on streptavidin-coated microtiter 
plates (Roche, Basel, Switzerland, cat. 11940279). The clones with the best OD displacement profiles (data not 
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shown) were used to generate antibodies that were purified using protein G columns according to the manufac-
turer’s instructions (GE Healthcare Life Sciences, Little Chalfont, UK, cat. 17-0404-01).
GpDpLQ1237 assay protocol. Optimal assay buffer, incubation times, temperature, and concentrations of 
antibody and peptides were determined and the finalised GPDPLQ1237 competitive ELISA protocol is described 
below. A 96-well streptavidin plate was coated with 100 µl of 625 pg/ml biotinylated peptide dissolved in coating 
buffer (10 mM phosphate-buffered saline [PBS] with 1% bovine serum albumin and 0.1% Tween 20 [PBS-BTB], 
8 g/l NaCl, pH 7.4) and incubated for 30 minutes at 20 °C. 20 μl of peptide calibrators prepared as a 3-fold dilution 
series of 30.03 ng/ml standard peptide, controls or samples were added to the appropriate wells followed by 100 μl 
of antibody NB427-5G11-4W3 dissolved in assay buffer (50 mM PBS-BTB, 8 g/l NaCl, pH 7.4) to a concentration 
of 526 ng/ml and incubation for 20 ± 1 hours at 4 °C. 100 µl of horseradish peroxidase (HRP)-conjugated rabbit 
anti-mouse secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, cat. 315-035-045) dis-
solved in assay buffer to a concentration of 160 ng/ml was added to the wells and incubated for 1 hour at 20 °C. All 
the above incubation steps included shaking at 300 rpm and were followed by five washes in washing buffer (25 mM 
Tris, 50 mM NaCl, 0.1% Tween 20, pH 7.2). Finally, 100 μl 3,3′,5,5′-tetramethylbenzidine (TMB, Kem-En-Tec 
Diagnostics, Taastrup, Denmark, cat. 4380) was added and incubated for 15 minutes at 20 °C in the dark with 
shaking at 300 rpm followed by the addition of 100 μl of 0.18 M H2SO4 to stop the reaction. The absorbance was 
measured at 450 nm with 650 nm as a reference on a VersaMax (Molecular Devices, Sunnyvale, CA) and a stand-
ard curve was plotted using a 4-parametric mathematical fit model in SoftMax Pro v.6.3 for Windows (Molecular 
Devices, Sunnyvale, CA). Cartilage resorption supernatants were diluted 1:1–1:5 as needed, BEX supernatants were 
diluted approximately 1:1–1:4000 as needed, serum, plasma, and urine samples were measured undiluted. Any 
samples measuring below the lower limit of detection (LLOD) were assigned the LLOD as their result.
Technical validation. The technical performance of the ELISA was validated in the following tests: LLOD, 
upper limit of detection (ULOD), measuring range (LLOD–ULOD), linear range and dilution recovery, inter- 
and intra-assay variation, specificity, and analyte freeze-thaw stability. The LLOD was determined from three 
independent runs of 68 samples of the zero standard (i.e. assay buffer). The LLOD was calculated within each run 
as the mean + three standard deviations and the final LLOD was calculated as the mean of the three runs. The 
ULOD was determined from five independent runs of the highest standard, measured in duplicates. The mean 
concentrations of the duplicates, as calculated from the standard curve, were used to calculate a ULOD defined 
as the mean of the five measurements - three standard deviations. The linear range of the assay was estimated 
from dilution recovery tests by performing 2-fold dilution series of a heat-inactivated FBS sample and a culture 
supernatant from a BEX OT culture and calculating the percentage dilution recovery against different starting 
dilutions. The linear range was considered to be the longest range of measured concentrations that, when adjusted 
for dilution, had a dilution recovery within 100 ± 20% of the adjusted concentration of the starting dilution. Inter- 
and intra-assay variation was determined from five independents runs of six positive control samples—diluted 
FBS, diluted BEX OT, and sera from pig, horse, sheep and donkey measured in duplicates—and the inter- and 
intra-assay coefficients of variation (CVs) of each sample were calculated. Specificity was tested using elongated 
and truncated standard peptides (Table 1). The analyte stability was determined for one FBS sample and one BEX 
OT sample for up to four freeze-thaw cycles.
BEX cultures. BEXs were harvested by dissecting the outermost layer of articular cartilage from bovine knee 
joints and were cultured as previously described68. In brief, cartilage explants were placed in 96-well plates and 
incubated at 37 °C with 5% CO2 under serum-free conditions (n = 4–5 per condition). Each explant was cultured 
in 200 μl DMEM/F-12 medium for 21 days, with medium changes every 3–4 days, under one of the following 
conditions: without cytokines, with 10 ng/ml OSM and 20 ng/ml TNFα (OT) to stimulate MMP activity, OT sup-
plemented with 10 μM of the broad-spectrum MMP inhibitor GM600169, or OT supplemented with 10 μM of the 
cysteine protease inhibitor E-6470. The selection of inhibitors and dosages was made based on their previous use 
in cartilage explant37–39 and cartilage resorption cultures36 as well as their well-established effects on osteoclastic 
bone resorption57.
Articular cartilage resorption assays. Osteoclast-mediated degradation of bovine articular cartilage was 
performed as previously described36. In brief, bovine articular cartilage was isolated from the femoral condyles 
of three bovine knees, using a biopsy punch and a scalpel, followed by immersion in liquid nitrogen to render the 
cartilage metabolically inactive and subsequent fixation of the tissue in 70% ethanol at 4 °C for at least 5 days prior 
to use. Mature human osteoclasts were generated from CD14+ monocytes isolated from the peripheral blood of 
anonymised blood donors as previously described71,72. Osteoclasts were seeded on the cartilage in 96-well cul-
ture plates at a density of 1.0 × 105 cells/well and were cultured at 37 °C and 5% CO2 in alpha minimum essential 
medium (αMEM) containing 10% heat-inactivated FBS, 100 units/ml penicillin, 100 µg/ml streptomycin, 388 µg/l 
thymidine, 25 ng/ml macrophage colony-stimulating factor (M-CSF, R&D Systems, Minneapolis, MN) and 25 ng/
ml receptor activator of nuclear factor kappa-B ligand (RANKL, R&D Systems). The medium was supplemented 
with 5 µM E-64, 10 µM GM6001, 5 µM E-64 and 10 µM GM6001 combined (E-64/GM6001), or a DMSO vehicle 
(1:2000 in medium), all from Sigma-Aldrich (St. Louis, MO). The selection of inhibitors and dosages was made 
based on their well-established effects on osteoclastic bone resorption57 as well as their previous use in cartilage 
resorption36 and cartilage explant37–39 cultures. Cartilage without osteoclasts was cultured as background samples 
for biomarker measurements. The media were changed by demi-depletion after 24 hours. After an additional 3–4 
days the media were collected and stored at −20 °C until analysis. Three independent resorption assays (n = 3–6 
per condition) were performed in this study.
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CTX-II. CTX-II released from resorbed cartilage and BEX cultures was measured in the culture supernatants 
using the Serum Pre-Clinical CartiLaps ELISA (IDS, The Boldons, UK), according to the manufacturer’s instruc-
tions. Cartilage resorption supernatants were diluted 1:1–1:8. BEX supernatants were measured for CTX-II at a 
selection of relevant time points, based on the GPDPLQ1237 induction data (days 5, 7, 10, 14, 17, and 21), with 
samples diluted 1:5–1:500 as needed. Any samples measuring below the detection limit, as specified by the man-
ufacturer, were assigned the detection limit (3.7 pg/ml) as their result. The detection limit was adjusted to 18.5 pg/
ml for the BEX samples to compensate for the lowest dilution factor used being 1:5.
Immunohistochemistry. Knees from young adult (19–21 weeks) female Lewis rats were fixed in 10% for-
malin for 2 weeks followed by decalcification in 15% EDTA for 7 weeks. The decalcified knees were infiltrated 
with paraffin using a Tissue-Tek VIP 5 Jr. (Sakura Finetek, Alphen aan den Rijn, The Netherlands), embedded in 
paraffin, and cut into 5–6 µm thick coronal sections using a HM 360 microtome (Microm International GmbH, 
Walldorf, Germany). The sections were deparaffinised and subjected to heat-induced epitope retrieval in sodium 
citrate buffer (10 mM tri-sodium citrate dihydrate, 0.05% Tween 20, pH 6) at 60 °C overnight. The following day 
the sections were washed in tris-buffered saline (TBS) with 0.1% Tween 20 and 1% Triton X-100 (TBS-TT, used 
for all wash steps), blocked for endogenous peroxidase activity using 1.2% hydrogen peroxide in 70% ethanol, 
washed, incubated with blocking solution (0.5% casein sodium salt in TBS-TT) for 20 minutes at room temper-
ature, and incubated with the NB427-5G11-4W3 monoclonal antibody or a negative control mouse antibody 
(Agilent Technologies, Santa Clara, CA, cat. X0931)—dissolved in blocking solution to 5.1 µg/ml and 15.6 µg/
ml respectively—overnight at 4 °C. Then the sections were washed, incubated with an HRP-conjugated second-
ary antibody (Agilent Technologies, Santa Clara, CA, cat. K4001) for 30 minutes at room temperature, washed, 
incubated with diaminobenzidine (DAB) chromogen, rinsed in tap water, counterstained with Mayer’s haema-
toxylin, rinsed and mounted. Digital micrographs of the tibial articular cartilage and growth plate were obtained 
with an Olympus DP71 digital camera mounted on a BX-60 microscope with 10x and 20x objectives using the 
Olympus cellSens software (Olympus, Center Valley, PA). The brightness and contrast of each individual image 
was adjusted for clarity using the Fiji73 Brightness/Contrast tool in the automatic mode.
Statistical analysis. The BEX biomarker data were used to calculate the AUC of each explant. The group 
AUCs were analysed using the Kruskal-Wallis test with Dunn’s multiple comparisons test against the OT condition. 
Statistical significance was considered to be P < 0.05. Means ± standard errors of the mean (SEMs) and P-values 
from the multiple comparisons tests are reported in the results section. Statistical significance is indicated with 
symbols in the figure where *P < 0.05. Statistical comparisons and plotting of graphs were performed in GraphPad 
Prism v7.01 for Windows (GraphPad Software, La Jolla, CA). Graphs represent group means and SEMs.
For the statistical analysis of cartilage resorption assays, the background biomarker measurements 
were subtracted from all other conditions within the same resorption assay, n = 3–6 per condition. The 
background-subtracted data were normalised to the vehicle condition mean. The mean percentages of each con-
dition from each resorption assay were pooled for analysis (n = 2 for E-64/GM6001 and n = 3 for other con-
ditions, n represents the number of resorption assays the condition was used in), reported as percentages of 
the vehicle ± SEMs. The data were analysed with a two-tailed one-way analysis of variance (ANOVA), with the 
assumption that the data were normally distributed, followed by either Tukey (for GPDPLQ1237) or Dunnett’s T3 
(for CTX-II) post hoc tests depending on whether or not equal variances could be assumed based on Levene’s test. 
Statistical significance was considered to be P < 0.05. Significance levels from the post hoc tests, relative to the 
vehicle condition (unless otherwise specified), are reported with P-values in the results section and using symbols 
in the figure where *P < 0.05 and **P < 0.01. Statistical comparisons were performed using IBM SPSS Statistics 
v24.0.0.0 64-bit edition for Windows (IBM, Armonk, NY). Graphs were plotted in GraphPad Prism v7.01 for 
Windows (GraphPad Software, La Jolla, CA) and represent group means and SEMs.
Ethical approval. Mouse immunisation procedures were approved by the Beijing Administration Office of 
Laboratory Animal and the animal ethics committee of Nordic Bioscience (Beijing).
The use of peripheral blood from anonymised blood donors, obtained from a blood bank, for osteoclast cul-
tures in this study was covered by the general ethical approval for research use of donor material in accordance 
with the Transfusion Medicine Standards (TMS) of the Danish Society of Clinical Immunology (DSKI). Informed 
consent to participate as an anonymised healthy control was obtained from each of the participating donors 
in writing as part of standard practices at the blood bank at Rigshospitalet, Copenhagen University Hospital, 
Copenhagen, Denmark. Donors participated in compliance with the Helsinki Declaration.
Human serum, plasma, and urine from OA patients, RA patients, and healthy donors for GPDPLQ1237 meas-
urements were commercially sourced.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
References
 1. Valdes, A. M. et al. Large scale meta-analysis of urinary C-terminal telopeptide, serum cartilage oligomeric protein and matrix 
metalloprotease degraded type II collagen and their role in prevalence, incidence and progression of osteoarthritis. Osteoarthr. 
Cartil. 22, 683–9 (2014).
 2. Lohmander, L. S., Atley, L. M., Pietka, T. A. & Eyre, D. R. The release of crosslinked peptides from type II collagen into human 
synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum. 48, 3130–9 (2003).
 3. Leung, Y. Y., Huebner, J. L., Haaland, B., Wong, S. B. S. & Kraus, V. B. Synovial fluid pro-inflammatory profile differs according to the 
characteristics of knee pain. Osteoarthr. Cartil. 25, 1420–1427 (2017).
1 1Scientific RepoRts |          (2019) 9:3050  | https://doi.org/10.1038/s41598-019-39803-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
 4. Krabben, A., Huizinga, T. W. & Mil, A. H. Biomarkers for radiographic progression in rheumatoid arthritis. Curr. Pharm. Des. 21, 
147–69 (2015).
 5. Reijman, M. et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum. 50, 2471–8 (2004).
 6. Kraus, V. B. et al. Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers 
Consortium. Ann. Rheum. Dis. 76, 186–195 (2017).
 7. Garnero, P. et al. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients 
with knee osteoarthritis: relations with disease activity and joint damage. Ann. Rheum. Dis. 60, 619–26 (2001).
 8. Jordan, K. M. et al. Urinary CTX-II and glucosyl-galactosyl-pyridinoline are associated with the presence and severity of 
radiographic knee osteoarthritis in men. Ann. Rheum. Dis. 65, 871–7 (2006).
 9. Garnero, P., Peterfy, C., Zaim, S. & Schoenharting, M. Bone marrow abnormalities on magnetic resonance imaging are associated 
with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum. 52, 2822–9 (2005).
 10. Van Spil, W. E. et al. The ability of systemic biochemical markers to reflect presence, incidence, and progression of early-stage 
radiographic knee and hip osteoarthritis: data from CHECK. Osteoarthr. Cartil. 23, 1388–97 (2015).
 11. Thudium, C. S., Löfvall, H., Karsdal, M. A., Bay-Jensen, A.-C. & Bihlet, A. R. Protein biomarkers associated with pain mechanisms 
in osteoarthritis. J. Proteomics 190, 55–66 (2019).
 12. Garnero, P. et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint 
damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum. 46, 2847–56 (2002).
 13. Landewé, R. et al. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term 
radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum. 50, 1390–9 (2004).
 14. Young-Min, S. et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with 
traditional markers. Arthritis Rheum. 56, 3236–47 (2007).
 15. Marotte, H., Gineyts, E., Miossec, P. & Delmas, P. D. Effects of infliximab therapy on biological markers of synovium activity and 
cartilage breakdown in patients with rheumatoid arthritis. Ann. Rheum. Dis. 68, 1197–200 (2009).
 16. Freeston, J. E. et al. Urinary type II collagen C-terminal peptide is associated with synovitis and predicts structural bone loss in very 
early inflammatory arthritis. Ann. Rheum. Dis. 70, 331–3 (2011).
 17. Oestergaard, S. et al. The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid 
samples for estimation of articular cartilage status in experimental models of destructive joint diseases. Osteoarthr. Cartil. 14, 670–9 
(2006).
 18. Oestergaard, S. et al. Early elevation in circulating levels of C-telopeptides of type II collagen predicts structural damage in articular 
cartilage in the rodent model of collagen-induced arthritis. Arthritis Rheum. 54, 2886–90 (2006).
 19. Oestergaard, S. et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular 
cartilage in rats: implications of the time of initiation. Arthritis Rheum. 54, 2441–51 (2006).
 20. Nielsen, R. H., Christiansen, C., Stolina, M. & Karsdal, M. A. Oestrogen exhibits type II collagen protective effects and attenuates 
collagen-induced arthritis in rats. Clin. Exp. Immunol. 152, 21–7 (2008).
 21. Duclos, M. E. et al. Significance of the serum CTX-II level in an osteoarthritis animal model: a 5-month longitudinal study. 
Osteoarthr. Cartil. 18, 1467–76 (2010).
 22. Kraus, V. B. et al. Urea as a passive transport marker for arthritis biomarker studies. Arthritis Rheum. 46, 420–7 (2002).
 23. Karsdal, M. A. et al. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis–the effect of sex, 
Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC 
Musculoskelet. Disord. 11, 125 (2010).
 24. Schaller, S. et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and 
degenerative joint diseases: how biomarkers can assist? Assay Drug Dev. Technol. 3, 553–80 (2005).
 25. Christgau, S. et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 29, 209–15 (2001).
 26. Eyre, D. R. Cartilage resorption assays. US6255056B1 (2001).
 27. Eyre, D. R. Cartilage resorption assays measuring type II collagen fragments. US6348320B1 (2002).
 28. Eyre, D. R. Synthetic peptides of type II collagen for cartilage resorption assays. US6566492B2 (2003).
 29. Bay-Jensen, A.-C. et al. Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human 
osteoarthritic knee cartilage. Osteoarthr. Cartil. 16, 615–23 (2008).
 30. Blaney Davidson, E. N., Vitters, E. L., van der Kraan, P. M. & van den Berg, W. B. Expression of transforming growth factor-β (TGFβ) 
and the TGFβ signalling molecule SMAD-2P in spontaneous and instability-induced osteoarthritis: role in cartilage degradation, 
chondrogenesis and osteophyte formation. Ann. Rheum. Dis. 65, 1414–21 (2006).
 31. Diarra, D. et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13, 156–63 (2007).
 32. Schett, G., Hayer, S., Zwerina, J., Redlich, K. & Smolen, J. S. Mechanisms of Disease: the link between RANKL and arthritic bone 
disease. Nat. Clin. Pract. Rheumatol. 1, 47–54 (2005).
 33. Schett, G. et al. Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum. 52, 3192–201 (2005).
 34. Stolina, M. et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J. 
Bone Miner. Res. 20, 1756–65 (2005).
 35. Goldring, S. R. & Goldring, M. B. Changes in the osteochondral unit during osteoarthritis: structure, function and cartilage-bone 
crosstalk. Nat. Rev. Rheumatol. 12, 632–644 (2016).
 36. Löfvall, H. et al. Osteoclasts degrade bone and cartilage knee joint compartments through different resorption processes. Arthritis 
Res. Ther. 20, 67 (2018).
 37. Sondergaard, B. C. et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated 
articular cartilage degradation. Osteoarthr. Cartil. 14, 738–48 (2006).
 38. He, Y. et al. The effect of protease inhibitors on the induction of osteoarthritis-related biomarkers in bovine full-depth cartilage 
explants. PLoS One 10, e0122700 (2015).
 39. Bay-Jensen, A.-C. et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, 
CIIM—increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin. Biochem. 44, 423–9 (2011).
 40. Siebuhr, A. S. et al. Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover. 
Osteoarthr. Cartil. 22, 44–50 (2014).
 41. Maijer, K. I. et al. Neo-Epitopes—Fragments of Cartilage and Connective Tissue Degradation in Early Rheumatoid Arthritis and 
Unclassified Arthritis. PLoS One 11, e0149329 (2016).
 42. Bay-Jensen, A. C. et al. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and 
bone in the LITHE study. Semin. Arthritis Rheum. 43, 470–8 (2014).
 43. Bay-Jensen, A. C. et al. Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab 
in the LITHE study. Arthritis Res. Ther. 18, 13 (2016).
 44. Bay-Jensen, A. C. et al. Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-
derived collagen species: A cross-sectional study. Rheumatol. Int. 32, 3565–3572 (2012).
 45. Bay-Jensen, A. C. et al. Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic 
markers of rheumatoid arthritis and ankylosing spondylitis. PLoS One 8, e54504 (2013).
 46. Noé, B. et al. C2K77 ELISA detects cleavage of type II collagen by cathepsin K in equine articular cartilage. Osteoarthr. Cartil. 25, 
2119–2126 (2017).
1 2Scientific RepoRts |          (2019) 9:3050  | https://doi.org/10.1038/s41598-019-39803-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
 47. Almeida, P. C. et al. Cathepsin B activity regulation. Heparin-like glycosaminogylcans protect human cathepsin B from alkaline 
pH-induced inactivation. J. Biol. Chem. 276, 944–51 (2001).
 48. Mehraban, F., Tindal, M. H., Proffitt, M. M. & Moskowitz, R. W. Temporal pattern of cysteine endopeptidase (cathepsin B) 
expression in cartilage and synovium from rabbit knees with experimental osteoarthritis: gene expression in chondrocytes in 
response to interleukin-1 and matrix depletion. Ann. Rheum. Dis. 56, 108–15 (1997).
 49. Ben-Aderet, L. et al. Detecting cathepsin activity in human osteoarthritis via activity-based probes. Arthritis Res. Ther. 17, 69 (2015).
 50. Charni-Ben Tabassi, N. et al. The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human 
cartilage collagen degradation. Osteoarthr. Cartil. 16, 1183–91 (2008).
 51. Montaser, M., Lalmanach, G. & Mach, L. CA-074, but not its methyl ester CA-074Me, is a selective inhibitor of cathepsin B within 
living cells. Biol. Chem. 383, 1305–8 (2002).
 52. Drake, F. H. et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 271, 
12511–6 (1996).
 53. Goto, T., Yamaza, T. & Tanaka, T. Cathepsins in the osteoclast. J. Electron Microsc. (Tokyo). 52, 551–8 (2003).
 54. Gelb, B. D., Shi, G. P., Chapman, H. A. & Desnick, R. J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. 
Science 273, 1236–8 (1996).
 55. Leung, P., Pickarski, M., Zhuo, Y., Masarachia, P. J. & Duong, L. T. The effects of the cathepsin K inhibitor odanacatib on osteoclastic 
bone resorption and vesicular trafficking. Bone 49, 623–35 (2011).
 56. Zhuo, Y., Gauthier, J.-Y., Black, W. C., Percival, M. D. & Duong, L. T. Inhibition of bone resorption by the cathepsin K inhibitor 
odanacatib is fully reversible. Bone 67, 269–80 (2014).
 57. Neutzsky-Wulff, A. V. et al. Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption - 
implications for osteoclast quality. BMC Musculoskelet. Disord. 11, 109 (2010).
 58. Brage, M., Abrahamson, M., Lindström, V., Grubb, A. & Lerner, U. H. Different cysteine proteinases involved in bone resorption and 
osteoclast formation. Calcif. Tissue Int. 76, 439–47 (2005).
 59. Everts, V. et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: 
differences between calvaria and long bone. J. Bone Miner. Res. 21, 1399–408 (2006).
 60. Henriksen, K. et al. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification. J. Bone 
Miner. Res. 21, 58–66 (2006).
 61. Catterall, J., Dewitt Parr, S., Fagerlund, K. & Caterson, B. CTX-II is a marker of cartilage degradation but not of bone turnover 
Abstract. Osteoarthr. Cartil. 21, S77 (2013).
 62. Bay-Jensen, A.-C. et al. The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique 
compared with other markers of collagen turnover. Arthritis Res. Ther. 11, R9 (2009).
 63. Mackie, E. J., Ahmed, Y. A., Tatarczuch, L., Chen, K.-S. & Mirams, M. Endochondral ossification: how cartilage is converted into 
bone in the developing skeleton. Int. J. Biochem. Cell Biol. 40, 46–62 (2008).
 64. Karsdal, M. A., Genovese, F., Madsen, E. A., Manon-Jensen, T. & Schuppan, D. Collagen and tissue turnover as a function of age: 
Implications for fibrosis. J. Hepatol. 64, 103–9 (2016).
 65. Mort, J. S. et al. Early cathepsin K degradation of type II collagen in vitro and in vivo in articular cartilage. Osteoarthr. Cartil. 24, 
1461–9 (2016).
 66. Combet, C., Blanchet, C., Geourjon, C. & Deléage, G. NPS@: network protein sequence analysis. Trends Biochem. Sci. 25, 147–50 
(2000).
 67. Gefter, M. L., Margulies, D. H. & Scharff, M. D. A simple method for polyethylene glycol-promoted hybridization of mouse myeloma 
cells. Somatic Cell Genet. 3, 231–6 (1977).
 68. Hui, W., Rowan, A. D., Richards, C. D. & Cawston, T. E. Oncostatin M in combination with tumor necrosis factor alpha induces 
cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum. 48, 3404–18 (2003).
 69. Hao, J. L. et al. Effect of galardin on collagen degradation by Pseudomonas aeruginosa. Exp. Eye Res. 69, 595–601 (1999).
 70. Bossard, M. J. et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate 
identification. J. Biol. Chem. 271, 12517–24 (1996).
 71. Sørensen, M. G. et al. Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J. Bone Miner. 
Metab. 25, 36–45 (2007).
 72. Henriksen, K., Karsdal, M. A., Taylor, A., Tosh, D. & Coxon, F. P. Generation of human osteoclasts from peripheral blood. Methods 
Mol. Biol. 816, 159–75 (2012).
 73. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–82 (2012).
Acknowledgements
We acknowledge the funding by the Danish Science Foundation (“Den Danske Forskningsfond”). H.L. is 
supported by Marie Curie Initial Training Networks (Euroclast, FP7-People-2013-ITN: #607446). A.K. is 
supported by Marie Curie Initial Training Networks (BonePain, H2020-MSCA-ITN-2014: #642720).
Author Contributions
H.L., K.H. and C.S.T. conceived of and designed the study. H.L. developed and validated the GPDPLQ1237 ELISA, 
carried out biomarker measurements, and analysed the data. A.K. carried out BEX experiments and rat tissue 
isolation. A.D. performed immunohistochemical stainings. M.H.D. provided the human peripheral blood 
for osteoclast cultures. All authors contributed to data interpretation. H.L. wrote the manuscript. All authors 
critically reviewed the manuscript for intellectual content. All authors read and approved the final manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-39803-0.
Competing Interests: H.L. performs research at Nordic Bioscience. A.K., M.A.K., Y.L., Y.H., T.M.J., A.C.B.J., 
C.S.T. and K.H. are employees of Nordic Bioscience. M.A.K., T.M.J., A.C.B.J. and K.H. hold stocks in Nordic 
Bioscience. Nordic Bioscience is a company involved in the discovery and development of biochemical 
biomarkers. A.D. and M.H.D. declare that they have no competing interests. The funders had no role in study 
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
13Scientific RepoRts |          (2019) 9:3050  | https://doi.org/10.1038/s41598-019-39803-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
